Alligator Bioscience to Participate in Upcoming Industry Conferences in October 2023

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that senior company representatives will participate in the following conferences during October 2023:

“Aktiedagen i Lund" by Aktiespararna, October 9, Lund
Søren Bregenholt, Chief Executive Officer of Alligator Bioscience, will present the company, its latest developments and upcoming catalysts to investors at 8.25 am/pm CET. More information about the event can be found here (information in Swedish).
6th LSX Nordic Congress, October 10-11, Copenhagen
Søren Bregenholt, Chief Executive Officer of Alligator Bioscience, will take part in the Biotech Plenary panel entitled "Revolutionizing Oncology Drug Discovery: Novel Approaches And Technologies Shaping The Future Of Cancer Treatment" at 2.50 pm CET on October 11. More information about the conference can be found here.

About Alligator Bioscience

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc.

Alligator Bioscience’s shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden.

For more information, please visit alligatorbioscience.com.

Categorized as